137 related articles for article (PubMed ID: 18717740)
1. von Willebrand factor content in Alphanate.
Logan LJ
Haemophilia; 2009 Jan; 15(1):369; author reply 370-1. PubMed ID: 18717740
[No Abstract] [Full Text] [Related]
2. Efficacy of factor VIII/von Willebrand factor concentrate Alphanate in preventing excessive bleeding during surgery in subjects with von Willebrand disease.
Rivard GE; Aledort L;
Haemophilia; 2008 Mar; 14(2):271-5. PubMed ID: 18194310
[TBL] [Abstract][Full Text] [Related]
3. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
[TBL] [Abstract][Full Text] [Related]
4. Update on the management of von Willebrand disease.
Federici AB
Clin Adv Hematol Oncol; 2008 Jan; 6(1):29-30. PubMed ID: 18322438
[No Abstract] [Full Text] [Related]
5. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
Michiels JJ; van Vliet HH; Berneman Z; Schroyens W; Gadisseur A
Acta Haematol; 2009; 121(2-3):167-76. PubMed ID: 19506363
[TBL] [Abstract][Full Text] [Related]
6. New treatment for von Willebrand disease.
Belavic JM
Nurse Pract; 2010 Sep; 35(9):13-4. PubMed ID: 20720463
[No Abstract] [Full Text] [Related]
7. von Willebrand disease in the 21st century: current approaches and new challenges.
Mannucci PM; Federici AB; James AH; Kessler CM
Haemophilia; 2009 Sep; 15(5):1154-8. PubMed ID: 19624761
[No Abstract] [Full Text] [Related]
8. Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate.
Berntorp E; Windyga J;
Haemophilia; 2009 Jan; 15(1):122-30. PubMed ID: 19149848
[TBL] [Abstract][Full Text] [Related]
9. Autosomal recessive von Willebrand disease type 1 or 2 due to homozygous or compound heterozygous mutations in the von Willebrand factor gene. A single center experience on molecular heterogeneity and laboratory features in 12 families.
Castaman G; Giacomelli S; Rodeghiero F
Acta Haematol; 2009; 121(2-3):106-10. PubMed ID: 19506356
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of D-arginine vasopressin in von Willebrand's disease.
Bala L; Boggio L; Green D
Curr Hematol Rep; 2005 Jan; 4(1):1-2. PubMed ID: 15610653
[No Abstract] [Full Text] [Related]
11. Factor VIII-von Willebrand factor binding defects in autosomal recessive von Willebrand disease type Normandy and in mild hemophilia A. New insights into factor VIII-von Willebrand factor interactions.
Jacquemin M
Acta Haematol; 2009; 121(2-3):102-5. PubMed ID: 19506355
[TBL] [Abstract][Full Text] [Related]
12. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
[TBL] [Abstract][Full Text] [Related]
13. Regulation of factor VIII expression and activity by von Willebrand factor.
Kaufman RJ; Pipe SW
Thromb Haemost; 1999 Aug; 82(2):201-8. PubMed ID: 10605705
[No Abstract] [Full Text] [Related]
14. Factor VIII and von Willebrand factor.
Vlot AJ; Koppelman SJ; Bouma BN; Sixma JJ
Thromb Haemost; 1998 Mar; 79(3):456-65. PubMed ID: 9531024
[No Abstract] [Full Text] [Related]
15. Haemate P/Humate-P for the treatment of von Willebrand disease: considerations for use and clinical experience.
Auerswald G; Kreuz W
Haemophilia; 2008 Nov; 14 Suppl 5():39-46. PubMed ID: 18786009
[TBL] [Abstract][Full Text] [Related]
16. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene.
Gadisseur A; van der Planken M; Schroyens W; Berneman Z; Michiels JJ
Acta Haematol; 2009; 121(2-3):145-53. PubMed ID: 19506361
[TBL] [Abstract][Full Text] [Related]
17. Haemate P von Willebrand factor/factor VIII concentrate: 25 years of clinical experience.
Schramm W
Haemophilia; 2008 Nov; 14 Suppl 5():3-10. PubMed ID: 18786006
[TBL] [Abstract][Full Text] [Related]
18. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.
Michiels JJ; Gadisseur A; Vangenegten I; Schroyens W; Berneman Z
Acta Haematol; 2009; 121(2-3):119-27. PubMed ID: 19506358
[TBL] [Abstract][Full Text] [Related]
19. von Willebrand's disease: from discovery to therapy - milestones in the last 25 years.
Kreuz W
Haemophilia; 2008 Nov; 14 Suppl 5():1-2. PubMed ID: 18786005
[No Abstract] [Full Text] [Related]
20. Unraveling the mystery of von Willebrand factor.
Bouma BN; Van Mourik JA
J Thromb Haemost; 2006 Mar; 4(3):489-95. PubMed ID: 16460427
[No Abstract] [Full Text] [Related]
[Next] [New Search]
